Kontivia Beteiligungen, a Zurich based long term oriented investment firm advised by Kellerhals Carrard, led a group of swiss entrepreneurial families, advised by Baker McKenzie, in the acquisition of a majority stake in Walter Meier (
Tags :Nicolas Mosimann
Novartis hands over the Life-Science-Park Rhine Valley to GETEC Switzerland, the platform of a leading European energy supplier and contracting specialist GETEC Group. They are the new owner and operator of the properties and infrastructure
Kellerhals Carrard has reorganised and strengthened its Life Sciences team. It is now fully integrated into the value chain of its clients in the pharmaceutical, medical technology, health and nutrition sectors and is led by
Biognosys and Bruker Corporation announced a strategic partnership, in which Bruker has made a majority-ownership investment in the company. Several of Biognosys’ earlier investors have sold their shares to Bruker in a secondary transaction, and
As we have informed here NLS Pharmaceutics, a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announced that it has
Kellerhals Carrard acted as Swiss legal advisor to MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company elevating care with innovative immunology therapeutics, in the closing of its previously announced business combination with Helix Acquisition Corp. (“Helix”), a
Katadyn Group, a Swiss-based specialist in portable water filters and trekking food, has been acquired by a group of entrepreneurs led by Kontivia, a long-term, down-to-earth investment company and
Helix Acquisition Corp, a Nasdaq-listed special purpose acquisition company and MoonLake Immunotherapeutics, a Swiss based clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases agreed on a business combination. At
MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseaseshas closed a Series A financing round, lead by BVF Partners LP. Other investors included Merck KGaA, Darmstadt, Germany.
The Kellerhals Carrard Startup Desk acted as legal counsel to Qnami, a Quantum Tech startup, in closing its Series A Financing Round raising a total of CHF 4 million. Led by the Venture Capital Funds Runa
